Knoll Pharma has declared a 33% drop in net profits for the year ended November'01. The company has changed its accounting year from December to November year ending. Hence the latest results are not strictly comparable as this year of the company was for a period of 11 months.
(Rs m) | FY01 | FY02 | % Change |
Sales | 3,333 | 3,246 | -2.6% |
Other Income | 310 | 166 | -46.5% |
Expenditure | 2,860 | 2,720 | -4.9% |
Operating Profit (EBDIT) | 473 | 526 | 11.1% |
Operating Profit Margin (%) | 14.2% | 16.2% | 14.1% |
Interest | 15 | 1 | -91.8% |
Depreciation | 53 | 45 | -15.9% |
Profit before Tax | 715 | 646 | -9.7% |
Extraordinary Income | 132 | - | |
Tax | 125 | 159 | 27.4% |
Profit after Tax/(Loss) | 722 | 487 | -32.6% |
Net profit margin (%) | 21.7% | 15.0% | |
No. of Shares (eoy) (m) | 16 | 16 | |
Diluted Earnings per share* | 44.6 | 30.1 | |
P/E (at current price) | 10.2 | ||
(*- annualised) |
On an annualised basis however, sales have registered a growth of more than 6%. Operating margins showed a good improvement of 200 basis points. The jump in operating margins was on the back of upward revision of four formulations of Insulin injection in March. Insulin Vial prices have increased by 22% - 25% since then. Insulin is the biggest revenue churner for Knoll where the company has a market share of close to 60%. Other income was on account of sale of mutual fund units of Rs 58 m and dividend received from wholly owned subsidiary.
Knoll Pharma seems to be in a consolidation mood. The company is in the process of taking shareholder permission to sell/divest its manufacturing unit at Pune and for the buyback of its shares. It plans to sell its plant as a going concern. It is proposing buyback of shares at a maximum price of Rs 350 per share. The markets however, seem to have sensed the proposal ahead of time, with the stock price appreciating more than 30% in last two months.
Knoll Pharma has also proposed 100% dividend i.e. Rs 10 per share. The stock currently trades (cum dividend) at Rs 308. Considering, the dividend the stock still trades at 15% discount to the buyback price proposed by the company.The buyback however, is dependent on shareholder's approval.
For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More
Equitymaster requests your view! Post a comment on "Knoll Pharma: Consolidating operations". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!